Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Spencer

Showing results (81-90 of 311) with videos related to

Pageof 32
Sort By:
Leukemia & Lymphoma|February 15, 2012
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trialP Joy Ho, Ross D Brown, Andrew Spencer, et al.
Transplantation and Cellular Therapy|July 25, 2024
Cardiovascular and Metabolic Risk Incidence Among Adult Allogeneic Stem Cell Transplant Recipients: A Narrative ReviewJoanne L C Tan, Rahul D Barmanray, Bianca Cirone, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2021
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple MyelomaJesus G Berdeja, Jacob P Laubach, Joshua Richter, et al.
Bone Marrow Transplantation|December 2, 2020
Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myelomaJoanne L C Tan, Tongted Das, David Kliman, et al.
British Journal of Haematology|May 31, 2013
Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chainsDenise Lee, Anna Kalff, Michael Low, et al.
British Journal of Clinical Pharmacology|June 13, 2012
Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndromeJohn Coutsouvelis, Meredith Wiseman, Lisa Hui, et al.
Internal Medicine Journal|December 27, 2023
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registrySueh-Li Lim, Cameron Wellard, Elizabeth Moore, et al.
Leukemia & Lymphoma|March 15, 2022
Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparisonKatja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
British Journal of Haematology|February 6, 2015
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomideParisa Asvadi, Andrew Cuddihy, Rosanne D Dunn, et al.
Bone Marrow Transplantation|March 30, 2022
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myelomaMatthew J Rees, Ashish Panigrahi, Simon J Harrison, et al.
Pageof 32

Showing results (81-90 of 311) with videos related to

Sort By:
Pageof 32
Leukemia & Lymphoma|February 15, 2012
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trialP Joy Ho, Ross D Brown, Andrew Spencer, et al.
Transplantation and Cellular Therapy|July 25, 2024
Cardiovascular and Metabolic Risk Incidence Among Adult Allogeneic Stem Cell Transplant Recipients: A Narrative ReviewJoanne L C Tan, Rahul D Barmanray, Bianca Cirone, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2021
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple MyelomaJesus G Berdeja, Jacob P Laubach, Joshua Richter, et al.
Bone Marrow Transplantation|December 2, 2020
Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myelomaJoanne L C Tan, Tongted Das, David Kliman, et al.
British Journal of Haematology|May 31, 2013
Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chainsDenise Lee, Anna Kalff, Michael Low, et al.
British Journal of Clinical Pharmacology|June 13, 2012
Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndromeJohn Coutsouvelis, Meredith Wiseman, Lisa Hui, et al.
Internal Medicine Journal|December 27, 2023
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registrySueh-Li Lim, Cameron Wellard, Elizabeth Moore, et al.
Leukemia & Lymphoma|March 15, 2022
Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparisonKatja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
British Journal of Haematology|February 6, 2015
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomideParisa Asvadi, Andrew Cuddihy, Rosanne D Dunn, et al.
Bone Marrow Transplantation|March 30, 2022
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myelomaMatthew J Rees, Ashish Panigrahi, Simon J Harrison, et al.
Pageof 32